The outputs from the workshop are being taken away under the joint leadership of Cogent and the Skills Academy.

Share

Related Links

Related Stories

  • Babraham scientists reveal how white blood cells get activated in auto-immune disease, helping to target better drugs for these disorders
    Scientists at the Babraham Institute have discovered a critical piece of the jigsaw that explains how a type of immune cell – a white blood cell known as a neutrophil – is activated by antibodies. The research, published today in the journal Science Signaling, brings new understanding to how the Phosphatidylinositol 3-kinase (PI3K) signalling pathway is used to regulate neutrophil function. This may pave the way for the development of a strategy to specifically inhibit the inappropriate activation of these immune cells that is seen in auto-immune inflammatory conditions such as rheumatoid arthritis, glomerulonephritis and some skin blistering diseases.
  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Together we will beat cancer
    Despite the doom and gloom surrounding the pharmaceutical industry and the many commentaries highlighting inefficiencies of the sectors operating model, 2011 has proven to be a near-record year for approvals of innovative new drugs. These approvals include seven new cancer treatments with two of these (Pfizer’s crizotinib, Xalkori™ and Roche’s vemurafenib, Zelboraf™) made in conjunction with companion genetic tests, reinforcing the notion that the practice of stratified medicine has truly arrived. The forthcoming special issue of Drug Discovery Today on cancer highlights innovative contributions in basic, translational and clinical research made by UK scientists and clinicians in the fight against cancer.
  • Drug discovery in the next decade:innovation needed ASAP
    The pharmaceutical sector, a cornerstone of the healthcare industry, is undergoing dramaticchange, primarily caused by reduced output of new medicines from research and development(R&D) laboratories, drug pricing pressures, stricter regulatory environments and the overallcurrent economic downturn. This makes demands of all pharmaceutical companies to find better ways to increase their output of new drugs, through innovation, to both treat patients and meet their shareholders’ expectations.
    Members' Content
  • Horizon 2020: A new research framework for developing and sharing knowledge
    The European Federation of Pharmaceutical Industries and Associations (EFPIA), the voice of the research-based pharmaceutical industry in Europe, welcomes the launch of the European Commission’s new Framework for Research and Innovation: Horizon 2020.

Top 5 Stories

News

New body to support pharmaceutical industry employers

23 July 2009

The pharmaceutical sector is set to get its own body dedicated to identifying and addressing key skills issues.

Following a high-level workshop organized by the National Skills Academy Process Industries and Cogent Sector Skills Council, the new skills body will allow pharmaceutical employers to drive the skills agenda of the sector.

The workshop – which was chaired by Anthony Higham, Operations Director of Aesica Pharmaceuticals – brought together more than 30 of the UK’s biggest industry players and Government representatives to examine the specific skills issues and reach agreement on the priorities and actions necessary to support the industry. The joint outputs from the workshop are being taken away under the joint leadership of Cogent and the Skills Academy, and a range of subgroups will work on the issues before reconvening in Autumn to form an action plan.

The six key areas identified as priorities were risk-based assessment, which is now the focus of the Regulatory Authorities; careers and retention of staff; innovation in pharmaceutical operations; management and leadership in a global industry; graduates and higher level provision; and science, technology, engineering, and mathematics education and support for young people.

Summing up, Anthony Higham identified a number of common themes for the day: ‘Reflecting on the keynote speaker insights and the perspective of the delegates it is clear that the UK pharmaceutical industry needs to change in order to remain competitive. As with any change programme the most common failure mode is lack of leadership and direction, hence the importance of the workshop and the ongoing commitment by all delegates.

‘Clearly there is a need for consistency and the importance of a common voice from within the industry, the final themes discussed centred on the alignment and the need to avoid duplication from the various service providers in attendance at the workshop.’

Skills Academy Chief Executive Phil Jones added: ‘This is a key step in giving the pharmaceutical sector the equivalent of its own dedicated skills body. The sector has its own unique footprint and specific needs, and the aim of this body is to make sure that it is pharma employers who are driving their own skills agenda.’

If anyone who could not attend the event wishes to participate in the next stage of the process, they should contact either Ian Mains at the Skills Academy (i.mains@process.nsacademy.co.uk) or John Holton at Cogent (john.holton@cogent-ssc.com).

 

This article is featured in:
Companies and People

 

Comment on this article

You must be registered and logged in to leave a comment about this article.